Burlington, Massachusetts, USA, November 3, 2026
PAQ Therapeutics, a clinical-stage biotechnology company focused on developing innovative targeted protein degradation therapies for cancer, has announced that it will present the first clinical data for PT0253, its selective KRAS G12D degrader, at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2026). The late-breaking oral presentation is scheduled for November 20, 2026, in Barcelona, Spain, and will highlight initial safety findings and antitumor activity from the company’s ongoing Phase 1 clinical trial in patients with advanced solid tumors. The announcement represents an important milestone in PAQ Therapeutics’ oncology development programme, particularly in the field of targeted protein degradation for cancers driven by KRAS mutations. PT0253 is an investigational drug candidate designed to selectively eliminate the KRAS G12D protein, a cancer-associated protein that plays an important role in tumor growth and survival. The presentation will include clinical findings from patients with advanced cancers, including individuals who previously received KRAS-targeted therapies. Alongside the oral presentation, PAQ will also present preclinical research describing the molecular characteristics and therapeutic potential of PT0253. These scientific presentations highlight the company’s continued efforts to develop innovative treatments for patients with KRAS-driven cancers, where treatment resistance and limited therapeutic options remain significant challenges.
PT0253 Targets KRAS G12D Through Protein Degradation
The investigational drug PT0253 is a selective KRAS G12D degrader developed using targeted protein degradation technology. KRAS is a protein involved in regulating important cellular processes, including cell growth, proliferation and survival. Mutations in the KRAS gene can cause abnormal activation of these pathways, contributing to the development and progression of several cancers. The KRAS G12D mutation is particularly important in oncology because it occurs in multiple aggressive solid tumors, including pancreatic ductal adenocarcinoma, colorectal cancer and non-small cell lung cancer. Traditional targeted therapies generally attempt to inhibit the activity of disease-associated proteins. In contrast, targeted protein degradation aims to remove the unwanted protein from cells, potentially offering a different therapeutic approach to addressing cancer-driving mutations. PAQ Therapeutics is developing PT0253 to selectively degrade the mutant KRAS G12D protein and interfere with signaling pathways that support tumor growth. By reducing the abundance of this cancer-associated protein, the investigational treatment is intended to disrupt tumor-related biological activity. This approach is particularly relevant for patients whose cancers carry KRAS G12D mutations and who may have limited treatment options after disease progression or resistance to previous therapies. However, the therapeutic effectiveness of PT0253 remains under clinical investigation.
Phase 1 Clinical Trial Evaluates Safety and Antitumor Activity
PAQ Therapeutics is evaluating PT0253 in an ongoing Phase 1 clinical trial involving patients with KRAS G12D-mutated advanced solid tumors. The study is designed as an open-label, dose-escalation and dose-expansion investigation to assess the safety and tolerability of the drug candidate, determine appropriate dose levels and identify potential antitumor activity. The clinical programme also evaluates pharmacokinetic and pharmacodynamic characteristics to understand how the investigational treatment behaves in the body and influences its intended biological target. The trial includes patients with advanced solid tumors and explores potential treatment combinations in selected expansion groups. The first clinical findings will be presented in a late-breaking oral session titled “PT0253, a selective KRAS G12D degrader, shows a differentiated safety profile and antitumor activity, including after prior (K)RAS therapy, in advanced solid tumors.” The presentation is scheduled for November 20, 2026, from 12:36 p.m. to 12:44 p.m. Central European Time during Plenary Session 6. Alexander I. Spira will serve as the presenting author. The announcement indicates that the presentation will provide initial clinical evidence regarding safety and antitumor activity, including findings in patients previously treated with KRAS-targeted therapies. Detailed patient numbers, response rates and safety outcomes should be assessed from the actual scientific presentation rather than assumed from the announcement.
Advertisement
EORTC-NCI-AACR Symposium Highlights Oncology Innovation
The 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics will take place from November 18–20, 2026, in Barcelona, Spain. The international scientific meeting brings together oncology researchers, clinicians and biotechnology companies to discuss emerging discoveries in cancer biology, molecular targets and innovative therapeutic development. PAQ Therapeutics will contribute two scientific presentations focused on PT0253. In addition to the late-breaking oral presentation, the company will present Abstract 320, titled PT0253 is a potent and selective KRAS G12D degrader for treatment of cancers, in the New Drugs poster session on November 20. The poster will provide additional information about the compound’s preclinical profile and its potential application in KRAS-driven cancers. PAQ Therapeutics is headquartered in Burlington, Massachusetts, and maintains a clinical pipeline focused on targeted protein degradation. Its programmes include PT0253, a selective KRAS G12D degrader, and PT0511, a pan-KRAS degrader, both being investigated in Phase 1 clinical development for advanced solid tumors. Overall, the upcoming presentation represents an important scientific milestone for PAQ Therapeutics and highlights the growing interest in protein degradation as an innovative strategy for oncology drug development. Further clinical research will be necessary to establish the safety, efficacy and long-term therapeutic potential of PT0253.
Source: PAQ Therapeutics press release
